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Abstract Measurements of serum thyroglobulin (Tg) with
sensitive immunoassays are of great importance for the man-
agement of patients with differentiated thyroid carcinomas.
However, interference of circulating autoantibodies to Tg
(hTgAb) hampers the usefulness of most assays. We have
produced a panel of monoclonal antibodies (mAbs) selected
to bind Tg in the presence of Tg autoantibodies and developed
a sensitive immunoassay for Tg with minor interference by
hTgAbs. The antibodies were characterized by cross-
inhibition and immunoassay combination studies, as well as
affinity estimation. The within-run and total imprecision of the
assay were determined with 2664 samples in 60 separate runs.
Themost sensitive assay combination with superior protection
against autoantibodies consisted of two solid phase mAbs and
two tracer mAbs with distinct binding sites. The assay was
linear and displayed a wide dynamic range up to 1342 μg/l
with a functional sensitivity of 0.1 μg/l and a total imprecision
of less than 10%. There was good agreement between the new
high sensitive immunofluorometric assay (IFMA) and two
well-established Tg assays from Brahms Kryptor and Roche
Diagnostics. Mean difference between the new IFMA and the
Kryptor assay was 0.059 μg/l with a 95 % confidence interval
of −0.032 to 0.151 μg/l, whereas the mean difference between
the new IFMA and the Roche assay was −0.80 μg/l with a
95 % confidence interval of −1.24 to −0.35 μg/l.
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Introduction
Thyroglobulin (Tg) is a 670-kDa glycoprotein produced spe-
cifically by the follicular cells of the thyroid gland. The Tg
molecule consists of two identical subunits which undergo
extensive posttranslational modification including
glycolsylation, phosphorylation, sulfation, and iodination [1,
2]. Ultimately, thyroglobulin functions as a prohormone for
the thyroid hormones thyroxine (T4) and triiodothyronine
(T3), but it is also released from the thyroid gland and is
detectable in sera of most normal individuals.
The incidence of thyroid cancer has increased by 50% over
the past 25 years [3, 4]. The most important clinical applica-
tion of an immunoassay for thyroglobulin is in the follow-up
of patients with differentiated thyroid cancer (DTC) which
have undergone total thyroidectomy. DTCs are often diag-
nosed in the early decades of life, and recurrences can occur
many years after the primary treatment, necessitating life-long
monitoring with clinical examinations and serial serum Tg
measurements. The reoccurrence of serum Tg after thyroidec-
tomy and 131-iodine ablation strongly indicates metastatic
disease, and small elevation in the 0.2 μg/l range can be of
pathological significance. The treatment and follow-up of this
patient group have also changed, and the American Thyroid
Association guidelines suggest that Tg assays with functional
sensitivity of ~0.1 μg/l may reduce the need to perform TSH-
stimulated Tg measurements during the initial follow-up of
some patients [5–7]. Thus, the sensitivity of the assay is very
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important for its clinical usefulness. Another challenge is as-
say interference by human autoantibodies against thyroglob-
ulin (TgAb). In immunometric assays, these autoantibodies
can cause an underestimation of the thyroglobulin concentra-
tion and, consequently, reduce the usefulness of Tg in the
follow-up of these patients. Circulating autoantibodies to Tg
are often positive in patients with autoimmune thyroid dis-
eases, Hashimoto’s thyroiditis (HT), and Graves’ disease
(GD), but TgAbs can also be detected in patients with thyroid
carcinoma and in individuals with no apparent thyroid disease.
It has been shown that Tg autoantibodies are detected in ap-
proximately 20 % of patients with thyroid cancer and in ap-
proximately 10 % of normal individuals [8]. To reveal TgAb
interference in Tg assays, there are guidelines recommending
reliable TgAb detection prior to Tg testing by immunoassays
[8]. A negative TgAb test is used to verify the absence of
TgAb interference, whereas a positive TgAb test indicates that
the Tg concentration measured in the immunoassay may be
unreliable and give a falsely low/undetectable serum Tg con-
centration that could mask disease. This could have serious
consequences for the follow-up of patients with DTC which
have undergone total thyroidectomy, and unfortunately, it has
been reported that false-negative TgAb misclassification was
30–40% using manufacturer-recommended TgAb cutoffs [9].
Thus, there is a clear need for a new, improved, and highly
sensitive immunoassay for Tg with less interference by Tg
autoantibodies.
Here we describe the production of a panel of monoclonal
antibodies selected to bind Tg in the presence of human auto-
antibodies from cancer patients. We have further characterized
the antibody specificities and tested suitable antibody pairs for
construction of an immunofluorometric assay (IFMA) for Tg.
The assay was finally compared to two well-established im-
munoassays for Tg (Brahms Kryptor and Roche Diagnostics).
Materials and methods
Production of monoclonal antibodies
Female BALB/c mice (6–8 weeks of age; Harlan Olac Ltd.,
Oxon, UK) were primed by subcutaneous injections with
25 μg Tg emulsified in Freund’s complete adjuvant (for
antigen preparation see Supplemental data). Two booster im-
munizations of 30 μg of Tg (subcutaneous) in Freund’s in-
complete adjuvant were given 2–3 and 4–5 months later. One
month after the last boost immunization dose, four daily intra-
peritoneal boosts of 50–200 μg of Tg were given immediately
before splenectomy [10]. Experimental animals were treated
in accordance with institutional guidelines. Specific immune
response was determined by incubating 100 μl diluted blood
samples from immunized mice with 100 μl 125I-labelled Tg
(approximately 50,000 cpm) in 0.05 M Tris–HCl buffer pH
7.8 containing 1 % bovine serum albumin (BSA). Incubation
was performed at room temperature before free and bound
antigen was separated using sheep anti-mouse antibodies
(SAM) coupled to paramagnetic polymer particles
(Dynabeads M280, Life Technologies, Oslo, Norway), by
adding 100 μl of a 10 mg/ml suspension. The resulting hy-
bridomas were screened for anti-Tg monoclonal antibodies in
absence and presence of human anti-thyroglobulin antibodies
(for primary and secondary screening procedures, see
Supplemental data) [11]. After the second screening, hybrid-
omas were subcloned and selected clones were chosen for
further in vitro expansion. Antibodies were purified by
Protein A-Sepharose 4B (GE Healthcare Life Sciences,
Uppsala, Sweden) chromatography. Subtyping of mAbs was
performed using the IsoStrip Mouse Monoclonal Antibody
Isotyping Kit (Roche, Indianapolis, IN, USA).
Measuring human autoantibodies to TgAb
Human TgAb was analyzed using a competitive assay
(Brahms Kryptor, Henningsdorf, Germany) with a measuring
range between 10 and 850 kU/l. When TgAb levels were
above 850 kU/l, the samples were automatically diluted and
the measuring range for automatically dilution was 10–20,
000 kU/l.
Radiolabelling of Tg
Thyroglobulin and antibodies were iodinated by the indirect
iodogen method (Pierce, Rockford, IL, USA) with Na125I
(Amersham Pharmacia Biotech, Little Chalfont, UK) at an
equal molar ratio of protein to iodine. Iodinated protein was
stored at −20 °C in 50% ethylene glycol and 0.05MTris–HCl
buffer pH 7.8 containing 1 g/l BSA.
Conjugation of tracer antibodies with Eu3+-chelates
Purified antibodies were conjugated to a europium chelate
using the DELFIA Eu3+-Labelling kit (PerkinElmer Inc.,
Turku, Finland). The antibodies were labelled at room tem-
perature for 72 h with a 12.5-fold molar excess of the Eu3+-
chelate in 0.1 M Na-borate buffer, pH 8.6. Excess label was
removed by gel filtration on a PD 10 column (GE Healthcare
Life Sciences, Uppsala, Sweden) equilibrated with 0.05 M
Tris–HCl and 0.5 g/l NaN3 (pH 7.8). The stock conjugate
was stored at 4 °C in the Tris buffer. Before use, the stock
solution was further diluted to 50 μg/ml in a Tris buffer con-
taining 75 mg/ml of diethylenetriamine pentaacetic acid-
treated BSA (PerkinElmer Inc., Turku, Finland) and filtered
through a 0.22-μm sterile filter (GE Healthcare Life Sciences,
Germany).
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Preparation of F(ab')2 fragments
Monoclonal antibodies were fragmented essentially according
to the method of Milenic et al. [12]. Antibody in 0.05 M Tris
buffer pH 7.0 containing 0.1 M NaCl and 0.005 M EDTAwas
incubated at 37 °C for 2 h with bromelain (ID-Diluent 1;
DiaMed AG, Switzerland) in a weight ratio of 20:1. The en-
zymatic reaction was stopped by the addition of 1/10 volume
of freshly made 0.2 M N-ethyl maleimide. Products were pu-
rified at 4 °C on a protein A chromatography column equili-
brated with 0.1 M sodium phosphate buffer pH 8.2 and eluted
with a linear pH gradient from the pH 8.2 application buffer to
a pH 3.2 limit buffer (0.025 M citric acid, 0.025 NaH2PO4,
and 0.1 g/l NaN3). Purified F(ab')2 fragments were dialyzed
against 0.1 M sodium borate buffer pH 8.0.
Biotinylation of F(ab')2 and IgG capture antibodies
A fivefold molar excess of EZ-link Sulfo-NHS-LC Biotin
(Thermo Scientific, Rockford, USA) was added to the anti-
bodies contained in 0.15 M NaCl and 0.1 M sodium borate
(pH 8.0) and incubated for 30 min at room temperature. The
reaction was stopped by adding 1 M glycine, and free biotin
was removed by dialysis against 0.005 M Tris–HCl, 0.15 M
NaCl, and 0.5 g/l NaN3 (pH 7.8) or by gel filtration on a PD 10
column equilibrated with the Tris buffer. The final solution
was diluted to 50 μg/ml and filtered through a 0.22-μm sterile
filter.
Epitope mapping
Epitope mapping and grouping of antibodies were performed
by cross-inhibition, where binding of mAbs to the antigen was
performed in the absence of competing mAbs (reference sig-
nal) or in the presence of competing mAbs. Iodinated Tg (50,
000 cpm, approximately 20 ng) was allowed to react for 1 h
with 1 μg competing mAbs (100 × molar excess) in PBS
containing 10 g/l BSA. After incubation, 100 μl was trans-
ferred to breakapart microtiter wells coated with mAbs (1 μg/
well). The plates were incubated for 1 h with shaking and then
washed three times with wash solution, before counting of
bound radioactivity. Binding of 125I-Tg without inhibiting an-
tibody was used as a reference for each solid phase antibody,
and complete cross-inhibition was defined as >80 %
inhibition.
Affinity measurements
Dissociation constants (KD) for the monoclonal antibodies
were estimated from the concentration of free antibody (in
mol/l) needed to achieve half-maximal binding of Tg. Tubes
containing 100 μl 125I-Tg in 0.05 mol/l Tris–HCl with
0.1 mol/l NaCl and 0.1 % BSA were incubated with 100 μl
of increasing amounts (0.32–1000 ng/tube) of the antibodies
diluted in the same buffer. Free and bound antigen was sepa-
rated with an excess of sheep anti-mouse antibody coupled to
magnetizable polymer particles (Dynabeads M280; Life
Technologies, Oslo, Norway) followed by washing and
counting of radioactivity.
Surface plasmon resonance analysis
The binding kinetics of the Tg antibodies were determined by
surface plasmon resonance (SPR) using the BIAcore3000
SPR biosensor (Biacore Life Sciences, Little Chalfont, UK).
Tg antibodies were immobilized at low densities (between
100 and 200 resonance units (RU)) to CM5 chips using the
amino coupling protocol recommended in the BIApplications
Handbook. Tg was diluted in running buffer (0.01 M Hepes
pH 7.4, 0.15 M NaCl, 0.003 M EDTA, and 0.005 %
Surfactant P20) to five concentration levels (0.3–25 nM) and
injected sequentially with increasing concentration in a single
cycle at a flow rate of 50 μl/min. The Tg association was
allowed to proceed for 180 s followed by dissociation for
180 s. The temperature was kept constant at 25 °C in all runs.
The reference surface, a flow cell treated with binding buffer
without antigen, was used to correct for systematic noise and
instrument drift in every run. Also, prior to each Tg binding
cycle, buffer was injected for additional correction. The bind-
ing kinetics was calculated using the BIAevaluation software
version 4.1. Association and dissociation rate constants (ka
and kd) were determined by single cycle titration using the
simple biomolecular interaction model (A +B =AB) and
corrected for mass transfer.
Immunometric assays for thyroglobulin
Initial testing was performed with immunoradiometric assays
(see Supplemental data). Further testing was performed with
time-resolved immunofluorometric assays (TR-IFMAs).
Assay format The TR-IFMAs for Tg were performed in
streptavidin-coated 96-well microtiter plates with biotinylated
mAbs on solid phase and Eu3+-conjugated tracer mAbs. For
assaying samples, 200 μg/well of biotinylated mAb in 200 μl
DELFIA assay buffer (0.05 M Tris–HCl, 0.05 M NaCl,
0.02 M diethylene triamine penta acetic acid, 0.5 g/l NaN3,
0.1 ml/l Tween 20, 20 mg/l Amaranth, 0.5 g/l BSA, 0.5 g/l
bovine IgG, and 15 mg/l MAK33-IgG (Roche Applied
Science, Penzberg, Germany), pH 7.8) was incubated under
continuous shaking for 45 min before washing three times
with wash solution (0.05 M Tris–HCl, 0.15 M NaCl, 0.05 %
Tween 20, 0.1 % Germall, pH 7.8). Fifty microliters of cali-
brator or sample and 100 μl assay buffer were then added to
duplicate wells, followed by continuous shaking for 60 min.
Following three washes, 200 μg/well of Eu3+-labelled mAb in
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200 μl DELFIA assay buffer was added and plates incubated
for another 60 min with continuous shaking. After six washes,
200 μl/well of enhancement solution was added, followed by
incubation with shaking at room temperature for 5 min.
Fluorescence was measured in a time-resolved fluorometer
(Victor, PerkinElmer Inc., Turku, Finland).
Analytical recovery The ability of the various assays to de-
tect Tg in the absence and presence of human anti-
thyroglobulin antibodies (TgAb) was tested by pre-
incubation of 180 μl of a Tg standard of approximately
18 μg/l with 20 μl of individual sera containing human
TgAb ranging from 261 to 1756 kU/l or a pool of 35 different
sera each containing >500 kU/l of human TgAb. The total
concentration of TgAb in the pool of sera was 7225 kU/l. A
sample of standard matrix buffer (0.05 M Tris–HCl, 0.15 M
NaCl, 1 g/l Germall containing 60 g/l BSA, pH 7.4) replacing
the TgAb fraction served as the reference.
Multiple antibodies combined in the assays Antibody com-
binations were investigated using the IFMA procedure de-
scribed above. When two or three antibodies were tested si-
multaneously as solid phase, 0.1 μg/well of each antibodywas
applied. Similarly, half of the concentration for Eu tracer was
applied if two antibodies were tested in one assay. The final
assay variants were performed on an automated AutoDelfia
instrument.
Calibrators and controls
The calibrators were based on purified Tg obtained from hu-
man goiter tissue, as described above. Calibrators containing
0, 0.91, 3.4, 16.6, 94.5, 442, and 1342 μg/l Tg were prepared
by dilution of the purified Tg fraction in matrix buffer, and the
dilutions were standardized against the certified reference ma-
terial (CRM) 457 reference preparation and stored at −20 °C
in aliquots. After thawing, the calibrators were stored at 4 °C
and used within 2 weeks.
Control samples were PreciControls Tumor Marker from
Roche Diagnostics, at two levels, 0.5 and 45 μg/l, respective-
ly, and from pooled serum of thyroidectomized patients, with
value in the low range of approximately 0.2 μg/l. The control
samples were included in every run and analyzed in duplicate
before and after the patient samples.
The final TR-IFMA for Tg
The final assay for Tg was performed with two solid phase
antibodies (E40 and I24) and two tracer mAbs (E44 and E45).
The solid phase mAbs were modified to biotinylated (Fab')2
fragments, and the tracer mAbs were conjugated to the Eu3+-
chelate, as described in earlier sections. For assaying samples,
we used 100 ng/well of each biotinylated mAb and 100 ng/
well of each tracer mAb, and the assay was further performed
as described above.
Detection limit The limit of blank (LoB) and limit of detec-
tion (LoD) were determined according to Clinical Laboratory
Standards Institute (CLSI) Guideline EP17-A [13]. LoB was
defined as the mean of zero calibrator +1.645 times the stan-
dard deviation (SD) and calculated from 77 replicates. LoD
was defined as LoB+1.645 times the SD of a sample contain-
ing low concentration of Tg (0.26 μg/l) and calculated from
105 replicates.
Functional sensitivity, precision, and linearity The func-
tional sensitivity was defined as the lowest Tg concentration
measured with coefficient of variation (CV) of 20 %. The
within-run and total imprecision of the assay were determined
with 2664 samples in 60 separate runs. The concentrations of
the samples were measured in duplicates using different lots of
reagents and calibrators, and the testing period was 9 months.
Total imprecision was defined as the CVof all measured con-
centrations in all assay runs and calculated using MultiCalcTM
software. To determine the linearity on dilution, we performed
serial dilution of a serum sample with elevated Tg concentra-
tion (>1800μg/ml). The sample was diluted 2-, 10-, 50-, 250-,
1250-, and 6250-fold in calibration buffer. The measurements
were done in duplicate.
Patient samples
Two thousand six hundred sixty-four fresh serum samples
from the hospital routine laboratory were analyzed in our
new highly sensitive Tg (hsTg) assay. Out of these, 1218
had Tg concentration <0.91 μg/l, 281 had Tg concentration
between 0.91 and 3.4 μg/l, 553 had Tg concentration between
3.4 and 16.6 μg/l, 277 had Tg concentration between 16.6 and
94.5 μg/l, 159 had Tg concentration between 94.5 and
442 μg/l, and 176 had Tg concentration between 442 and
1342 μg/l.
In addition, 241 serum samples from 105 patients with
DTC (papillary or follicular thyroid cancer) were analyzed
simultaneously in our assay, a homogenous assay (Brahms
Kryptor, Henningsdorf, Germany) with a measuring
range between 0.09 and 200 μg/l and an electro-
chemiluminescence immunoassay (Roche Diagnostics,
Penzberg, Germany) with a measuring range between 0.04
and 500 μg/l. The samples were collected as part of the routine
sampling procedure in follow-up after treatment of DTC in
our hospital from 2009 to 2010. Seventy-four of the patients
had undergone rhTSH stimulation and had low initial Tg
values and negative/low values of human TgAb (<50 kU/l).
We analyzed two to three samples per patient, resulting in a
total of 210 samples. The final 31 samples were from 31
randomly selected patients with measurable Tg values and
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TgAb between 50 and 2934 kU/l. All samples were stored at
−30 °C. Every participant had given written informed consent
to participate in the study, and The Regional Committee for
Medical Research Ethics approved the study.
Statistical analysis
Spearman correlation and Deming regression analysis were
performed to compare the new assays with the two established
Tg assays from Brahms Kryptor and Roche Diagnostics. The
Tg values were log-transformed to obtain normal distribution,
and value <0.04 μg/l was set to 0.03 μg/l.
Results
Monoclonal antibody characteristics
Several monoclonal antibodies to thyroglobulin were obtained
after screening approximately 2000 hybridomas from two in-
dividual fusions. From the secondary screening, nine antibod-
ies were selected according to their ability to bind Tg in the
presence of anti-thyroglobulin autoantibodies. These antibod-
ies were subcloned and purified on a protein A column. The
purified antibodies were IgG subtyped. Six antibodies (E40,
E44, E47, I15, I24, and I25) were of the IgG1 subtype, while
three (E39, E41, and E45) were of the IgG2b subclass. All
possessed kappa light chains.
Epitope mapping
Characterization of which antibodies that was able to bind
simultaneously to thyroglobulin was evaluated by cross-
inhibition assays. Binding of the monoclonal antibodies to
Tg was performed in the presence of inhibiting mAbs already
bound to labelled antigen and in the absence of mAbs (refer-
ence signal), see Table 1. From the inhibition pattern, it was
possible to classify the monoclonal antibodies into five epi-
tope groups: A to E. Group D may be further subdivided
because E39 and E44 differ in their ability to inhibit the
mAb in group B.
IFMA combinations of antibody pairs
The results from the study of all antibody pairs in fluorometric
assay combinations are shown in Table 2. The results indicate
that antibodies belonging to groups A, B, and C are best as
solid phase antibodies, while group D and E mAbs behave
best as tracer antibodies. There are, however, a few other ac-
ceptable assay combinations, the other way around for solid
phase and tracer mAbs from these groups. Only mAb I24
(group B) can be used both as solid phase and tracer antibody
to establish an immunoassay with suitable response signals.
Antibody combinations in the presence
of antithyroglobulin autoantibodies
One of the purposes of this study was to select antibodies with
minor influence of autoantibodies to Tg which may be present
in patient serum. Thus, pairs of antibodies were tested for their
ability to determine Tg in the presence of human TgAb. Initial
IRMA measurements of Tg in the presence of autoantibodies
indicated that mAb E40 was superior to mAb I25, both be-
longing to group C. Results are not shown. Therefore, the
latter antibody was omitted in further experiments. Although
E45 and E47 were in the same group (group E), their excep-
tional ability to make sensitive assays made it reasonable to
include both antibodies in the further testing. Thus, we chose
I15, I24, or E40 as solid phase antibodies (groups A, B, and
C), respectively, with either E44, E45, or E47 as tracer anti-
bodies (groups D and E), respectively, in the presence of a
selection of patient sample containing autoantibodies. Figure
1 shows the results of these analyses. Eight individual patient
sera (TgAb ranging from 261 to 1756 kU/l) and a pool of 35
sera (TgAb=7224 kU/l) were included in IFMA combina-
tions of the six monoclonal antibodies. Analytical recovery
for the IFMA combinations differed considerably. Also, some
of the individual sera were more inhibiting than others for all
mAb combinations tested, and the pooled serum was highly
inhibiting for all combinations tested. However, no combina-
tion was unaffected by all the autoantibodies tested. The
IFMA combinations of E40 with E45 in Fig. 1b gave gener-
ally the best responses for a given concentration of Tg, while
antibody combinations of E40 with E44 and I24 with E45
(Fig. 1a, h) also distinguished by the best responses in the
assay for a given concentration of Tg. Thus, these results
indicate that E40, I24, E44, and E45 are the best candidate
antibodies for a sensitive and robust Tg assay.
Binding kinetics of the Tg antibodies E40, E44, E45, E47,
I15, and I24
The binding kinetics of the Tg antibodies were estimated
using two different methods, (1) from the concentration of
free antibody needed to achieve half-maximal binding of Tg
and (2) by SPR analysis using the BIAcore3000 SPR biosen-
sor (Table 3). The KD values estimated from equilibrium
analysis correlate quite well with the values obtained using
SPR analysis. Both methods showed that all antibodies (E44,
E45, E47, I15, and I24) had very high affinity for Tg with KD
values≤6×10−10 except for E40 which had a KD of 1×10−9.
The equilibrium analysis indicated that E45 and I24 had
the highest affinity for Tg with KD = 2 × 10
−10 for both,
while the SPR analysis indicated that E47 and I15 had
the highest Tg affinity with KD = 1.1 × 10
−10 and
KD= 2.6 × 10
−10, respectively.
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IFMA combinations with multiple mAbs as catcher
and tracer
Some of the immunoassays based on a pair of two antibodies
were superior to others in detecting serum Tg in the presence of
autoantibodies. However, none of these assays were unaffected
by every analyzed sample containing human TgAb. Therefore,
immunoassays combining multiple mAbs as catcher and/or
tracer were evaluated. Here, we included the same six antibod-
ies as above without excluding I15 and E47 for now. First,
combinations of two or three solid phase antibodies with each
of the tracer antibody candidates were tested for their perfor-
mance expressed by the responses obtained in a calibration
curve between 0 and 1342 μg/l. Only slight differences were
seen between the calibration curves, but the combination of
E40 and E24 was recognized as the best solid phase combina-
tion, results not shown. Further, combination of tracer antibod-
ies E44 and E45 and E44 and E47, respectively, compared to
only E45 were tested with the best solid phase combination
(E40+E24). Combining two tracer antibodies gave higher re-
sponses for the calibration curve compared to only one tracer,
but no significantly differences were observed between the
Table 1 Cross-inhibition
Group Solid phase mAb Inhibiting antibodies
Group A Group B Group C Group D Group E
I15 I24 I25 E40 E41 E39 E44 E45 E47
A I15 100 49 50 61 45 34 39 40 51
B I24 59 99 47 53 35 0 23 20 41
C I25 58 49 99 98 60 14 36 26 46
E40 56 51 98 99 64 35 44 40 51
E41 58 52 90 95 98 48 54 37 50
D E39 57 49 63 65 66 97 97 57 64
E44 55 48 73 74 70 97 99 38 58
E E45 59 45 59 58 54 63 77 99 99
E47 57 41 51 58 49 62 71 98 99
Complete inhibition >80 % is indicated in bold type













Group C Group D Group E
Eu-I15 Eu-I24 Eu-I25 Eu-E40 Eu-E44 Eu-E45 Eu-E47
A Bio-I15
-412 1685 568 30098 39053
B Bio-I24
7900 23218 -96 17355 28971 31264 36909
C Bio-I25
18938 24305 22 1980 30352 32140
Bio-E40
15185 26874 -102 -2214 25380 33130
D Bio-E44
11189 31560 664 28716 2604 36203 35802
E Bio-E45
14895 24347 -1322 22370 27097 2477 2730
Bio-E47
19528 37379 950 36 1707
The antibodies that were further used for testing analytical recovery in the presence of interfering autoantibodies are highlighted in bold. A Tg
concentration of 18 μg/ml is used in the experiment. White: cps (18 μg/ml—blank) ≤ 10,000, light grey: cps > 10,000 ≤ 30,000, grey:
cps > 30,000≤ 40,000, dark grey: cps > 40,000
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combinations E44 and E45 versus E44 and E47, results not
shown. Thus, because E45 were shown to be more unaffected
by human autoantibodies than E47, antibody E45 was consid-
ered a better tracer candidate than E47.
The final IFMA assay was therefore based on E40 and I24
as solid phase antibodies in combination with E44 and E45 as
tracer antibodies.
Performances of the final IFMA assay for Tg
Assay The final assay was automated on an AutoDelfia instru-
ment. To minimize the risk of heterophilic antibody interfer-
ence, modifications were introduced including the use of
F(ab')2 fragments as solid phase and irrelevant immunoglobulin
buffer additives [14]. Patient serum diluted to 0.2, 0.45, and
42.9 μg/l Tg was used to determine optimal assay kinetics.
The signals reached a plateau after a 30-min incubation for
the (Fab')2 capture reagents, 1 h for the antigen, and a final
incubation of 1 h with the Eu3+-labelled tracer antibodies (data
not shown). A typical calibration curve is presented in Fig. 2
together with an intra-assay precision profile. The assay
displayed a wide dynamic range with linearity up to 1342 μg/l.
Analytical validation LoB was determined from 77 separate
runs and calculated as 0.02 μg/l. LoD was determined from
the LoB and SD of a sample containing low concentration of
Tg (0.26 μg/l) in 105 separate runs and estimated to 0.05 μg/l.
The functional sensitivity, defined as the lowest Tg concentra-
tion measured with CVof 20 %, was assessed to be 0.1 μg/l
Bio-E40 and Eu-E44
Patient sera with hTgAb
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Fig. 1 Antibody combinations in the presence of eight individual patient
samples (TgAb ranging from 261 to 1756 kU/l) and one pool of patient
samples (TgAb = 7224 kU/l). ATg concentration of 18 μg/ml is used in
the experiment and the results shown as percent analytical recovery. Lines
representing mean analytical recoveries are also included in each figure
Table 3 Binding kinetics and affinities for the Tg antibodies E40, E44,
E45, E47, I15, and I24











E40 3.32× 105 3.69× 10−4 1.1 × 10−9 1.2 × 10−9
E44 3.14× 105 1.29× 10−4 4.1 × 10−10 3 × 10−10
E45 4.99× 105 1.98× 10−4 4.0 × 10−10 2 × 10−10
E47 2.95× 105 3.23× 10−5 1.1 × 10−10 6 × 10−10
I15 2.46× 105 6.29× 10−5 2.6 × 10−10 3 × 10−10
I24 4.24× 105 2.15× 10−4 5.1 × 10−10 2 × 10−10
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after 9 months of evaluation time using several different re-
agent and calibrator lots. Within-run and total imprecision of
the assay were determined with 2664 samples in 60 separate
runs. The variation between replicates was acceptable with a
total imprecision of less than 10 % (Fig. 2). The measured
mean concentrations of Tg controls were 0.26, 0.54, and
45 μg/l. The within-run imprecisions were 6.3, 4.3, and
2.3 %, and total imprecisions were 6.9, 6.9, and 3.6 %, respec-
tively. Linearity on dilution resulted in apparent mean recov-
eries of 67–95 % of expected in zero calibrator.
Comparison of the new IFMA for Tg with two
well-established Tg assays
Concentrations of Tg in 241 serum samples were determined
simultaneously by the newly developed IFMA and two com-
mercially available immunoassays for Tg, a homogenous as-
say (Brahms Kryptor) and a chemiluminescence assay (Roche
Diagnostics). Out of these samples, 74 were from patients
with low initial Tg values and negative/low values of human
TgAb (<50 kU/l) and who had undergone rhTSH stimulation.
We analyzed two to three samples per patients, resulting in a
total of 210 samples. The final 31 samples were from 31
randomly selected patients with measurable TgAb values
>50 kU/l (ranging from 50 to 2934 kU/l). The correlation
between the new IFMA and the Kryptor assay was y=ax+b
with a=1.06 (95 % CI= [1.02; 1.09]) and b=−0.09 ((95 %
CI = [−0.13; −0.04]), ρ = 0.79 (95 % CI = [0.74; 0.84]))
(Fig. 3). Due to inadequate sample volume in two of the sam-
ples, only 239 samples were evaluated in the Roche assay. The
correlation between the new IFMA and the Kryptor assay was
y=ax+b with a=0.93 (95 % CI= [0.91; 0.96]) and b=−0.20
((95 % CI= [−0.23; −0.16]), ρ=0.82 (95 % CI= [0.78; 0.86]))
(Fig. 4). Mean difference between the new IFMA and the
Kryptor assay was 0.059 μg/l (95 % CI= [−0.032; 0.15 μg/
l]), and thus, the new IFMA method and the Kryptor assay
gave similar results. Mean difference between the new IFMA
and the Roche assay was −0.80 μg/l (95 % CI = [−1.24;
−0.35μg/l]). Thus, the new IFMA tended to give lower results
than the Roche assay by between −1.24 and −0.35 μg/l.
Discussion
Thyroglobulin is a specific tumor marker for follow-up of
patients with DTC which have undergone total thyroidectomy
with or without postoperative 131-iodine ablation, and the
sensitivity of a Tg assay is important for a correct interpreta-
tion of clinical significance of minimal changes in serum Tg.
Tg [µg/l]





















100Fig. 2 Calibration curve (black
circle) and imprecision profile
(black down-pointing triangle)
for the final Tg assay. The
calibration curve is linear over a
range of 0.9–1342 μg/l
(y= 0.96x+ 3.81, R2 = 1). The
imprecision profile shows
CV<10 % over the entire
working range (N = 2664)























Fig. 3 Correlation between the new TR-IFMA and a homogenous assay
for detection of Tg (Brahms Kryptor) in 241 serum samples. Deming
regression line is included
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However, the presence of anti-Tg autoantibodies may mask
the epitopes used by reagent antibodies in an immunoassay
and cause an underestimation of the thyroglobulin concentra-
tion. The only currently available methodology that could
completely eliminate interference of TgAbs with the measure-
ment of Tg appears to be mass spectrometry. Liquid
chromatography-tandem mass spectrometry (LC-MS MS)
has shown promising results for measuring Tg in biological
samples with higher resistance against antibody interference
than the immunoassays [8]. However, because these methods
do not have the necessary functional sensitivity, have a com-
plex and manual workflow, and are not universally available,
Tg measurements with LC-MS MS should be restricted for
TgAb-positive serum samples [7, 8]. Thus, there is apparently
still a need for a highly sensitive Tg immunoassay with less
interference by Tg autoantibodies.
To make a new and improved immunoassay for Tg, we
have used a novel approach and selected monoclonal antibod-
ies in the presence of autoantibodies from patients with thy-
roid cancer. After screening approximately 2000 hybridomas,
nine antibodies were selected according to their ability to bind
Tg in the presence of anti-Tg autoantibodies. From their cross-
inhibition patterns, these antibodies were classified into five
epitope groups, A to E, where group D is comprised by two
subgroups. This is in agreement with earlier studies by Ruf et
al. and Piechaczyk et al. where ten and 15 murine monoclonal
antibodies against human Tg were classified into six epitope
clusters, respectively [15, 16]. In the study by Ruf et al., two
closely related groups failed to be classified in the same epi-
tope cluster because one antibody displayed an asymmetric
cross-inhibition pattern with one antibody in the other group,
resembling the subdivision of our group D due to differences
between mabs E39 and E44 in their ability to inhibit mAb I24
in group B. Our choice of antibodies from most of the defined
epitope groups indicates that we have a representative panel of
mAbs when selecting suitable antibody pairs for a new IFMA.
It is well known that some parts of the Tg molecule are
more prone to autoantibody interference than other, and it has
been shown that TgAbs recognize overlapping epitopes in an
immunodominant region on the Tg dimer with two major and
three minor epitopic regions [17]. There has also been shown
that epitope recognition patterns of TgAb are different in in-
dividuals who are euthyroid or have clinical disease and that
epitope recognition pattern may be of clinical and prognostic
relevance in TgAb-positive DTC patients [18]. TgAbs in pa-
tients with autoimmune thyroid diseases react with a few of
the antigenic determinants on Tg, and their serum levels are
elevated compared to serum levels in non-autoimmune dis-
eases [19, 20]. On the contrary, TgAbs in patients with thyroid
cancer and healthy individuals appear to be more heteroge-
neous [19, 21, 22]. However, several studies have also been
able to identify restricted TgAb recognition patterns in pa-
tients with thyroid cancer and indicated that it may be possible
to distinguish between patients with different thyroid diseases
and healthy individuals on the basis of the differences in TgAb
specificities [20, 23]. Finally, because of the large size and
structural complexity of the thyroglobulin molecule, the anti-
genic composition of Tg is still not well understood. Thus, it
seems to be impossible to make an immunoassay for Tg
completely protected against human autoantibodies.
However, our approach for minimizing the influence of hu-
man TgAbwas to test and select antibody pairs in the presence
of human TgAb in the form of individual sera and a pool of
sera consisting of 35 individual sera containing human TgAb.
Consequently, some of the individual sera as well as the
pooled serum were more inhibiting than others for all mAb
combinations tested, and the pooled serum was most likely
dominated by a few individual sera with highly elevated con-
centrations of human TgAb. Because some parts of the Tg
molecule are more prone to autoantibody interference than
other, this was as expected. In the final IFMA, we combined
four antibodies against four distinct epitopes on Tg to obtain
the highest sensitivity and the best possible protection against
autoantibodies. Consequently, by combining several antibod-
ies from different epitope groups, we have increased the prob-
ability of avoiding the negative effect of autoantibodies.
In the final assay, E40 and I24 were used as solid phase
antibodies in combination with E44 and E45 as tracer antibod-
ies. The antibodies were thoroughly characterized, and the
binding kinetics of the antibodies was estimated from equilib-
rium analysis and SPR analysis. All four assay antibodies had
acceptable binding affinities for construction of an immuno-
assay (2×10−10<KD<1×10
−9), and the differences between























Fig. 4 Correlation between the new TR-IFMA and a chemiluminescence
assay for detection of Tg (Roche Diagnostics) in 239 serum samples.
Deming regression line is included
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the KD values obtained with the individual methods were
within expected range when using two different methods.
With a functional sensitivity of 0.1 μg/l and a total impre-
cision of the assay less than 10%, our assay fulfills the criteria
of a highly sensitive assay for Tg, which is useful for manage-
ment of thyroid cancer [7]. As mentioned earlier, the sensitiv-
ity of the assay is important in the follow-up of DTC patients,
and for the clinician, even Tg values below 0.2 μg/l may
suggest no residual thyroid tissue or recurrence/metastasis of
the cancer after treatment. In a study by Iervasi et al. [19], it
was shown that Tg assays with sensitivities ranging between
0.1 and 1 μg/l may allow for earlier identification, particularly
for patients with minimal amounts of circulating Tg [24]. It
has also been shown that monitoring Tg with a sensitive im-
munoassay had comparable sensitivity to recombinant human
TSH-stimulated Tg in follow-up of thyroid cancer patients
[25]. It is likely that very low Tg concentrations do not
require immediate treatment and that serial measurements
of serum Tg are more informative than an absolute single
value and have additional clinical benefit [26]. Thus, our
new hsTg assay may have improved clinical value for
detection of recurrent disease and for serial measurements
in long-term follow-up.
Measuring Tg in samples with TgAb is still challenging;
however, a measurable Tg value in a TgAb-positive patient
gives the clinician valuable information even though the Tg
value might be false low leading to further examination as
ultrasonography.
Finally, there is a good agreement between the new IFMA
assay and the established Tg assays from Brahms Kryptor and
Roche Diagnostics; however, the new IFMA tended to give
lower results than the Roche assay by between −1.24 and
−0.35 μg/l. Differences in the assay antibodies characteristics
may explain these discrepancies even though both assays are
traceable to the same CRM 457. In a review by Clark et al.,
they state that although many assays are traceable to the same
reference material CRM 457, a wide scatter of results was
obtained [27]. The CRM457 was shown to contain both intact
Tg molecules and smaller molecular forms [27]. Thus, the
different assay antibodies may differently detect these variants
of the Tg molecule.
The potential underestimation of Tg concentrations caused
by autoantibodies hampers the usefulness of sensitive thyro-
globulin immunoassays; thus, this work can potentially im-
prove the clinical utility of the hsTg assay.
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